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Molecular Oncology Research (MORe) Foundation, Barcelona, SpainLung cancer is the leading cause of cancer-related death worldwide
and surgical resection is the treatment of choice for early-stage non-
small-cell lung cancer (NSCLC). However, in this subgroup of patients,
survival can range from 10% to 60% in stage II (with involvement of
lymph nodes — N1), and stage IIIA (involvement of mediastinal lymph
nodes—N2). Stage IA is themost favorable situationwith very small tu-
mors without lymph node metastasis. However, the risk of relapse is
still rather unpredictable despite the many prognostic gene signatures
that have been developed. In spite of the lack of commonality in many
genes identiﬁed in published prognostic signatures, numerous gene ex-
pression signatures perform overlapping prognostic functions and may
be able to provide uniform information on outcome in early NSCLC
(Rosell et al., 2011; Chen and Chen, 2014).
To this end, Chen and Chen have reported a lung cancer prognostic
index (LCPI) that includes the expression of seven genes and combines
with age and stage. The LCPI permits separation of patients into three
different risk groups (low, intermediate and high) following surgery.
Using this LCPI, patients classiﬁed as low risk of recurrence can be
deemed as not needing any further treatment. For patients deemed to
be at high risk, complete surgical resection is insufﬁcient treatment
and they will require further therapy. Intriguingly, for patients in low/
intermediate risk groups adjuvant chemotherapy could be detrimental
for survival (Chen and Chen, 2014).
What lessons can be learned from this LCPI? NSCLC has become rec-
ognized as being a heterogeneous set of diseases (Reck et al., 2013) and,
in patients with lung adenocarcinomas, epidermal growth factor recep-
tor (EGFR) mutations are associated with response to EGFR inhibitors.
Other potentially targetable oncogenes are HER2, MET, FGFR1 and KRAS
as well as fusion oncogenes involving anaplastic lymphoma kinase
(ALK), ROS1, neuregulin 1 (NGR1) and neurotrophic tyrosine kinase re-
ceptor 1 (NTRK1). These oncogenic lesions predict sensitivity to speciﬁc
inhibitors. Potentially targetable mutations have also been identiﬁed in
squamous cell carcinoma of the lung, such as discoidin domain-
containing receptor 1 (DDR2), FGFR1 and others. Therefore, in most
cases, adjuvant chemotherapy may not be the correct strategy. In the☆ The author declares no conﬂicts of interest.
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on patients with low/intermediate risk of relapse according to the LCPI
(Chen and Chen, 2014). Intriguingly, according to the LCPI for patients
with high risk, the effect of chemotherapy could be negligible. Two large
meta-analyses of adjuvant and preoperative chemotherapy in early
resected NSCLC show an absolute increase in survival of 4% at 5 years
(Arriagada et al., 2010, 2014). Neither meta-analysis showed clear evi-
dence that age, histology, and clinical stage beneﬁted more or less from
adjuvant or preoperative chemotherapy (Arriagada et al., 2010, 2014).
However, in the adjuvant chemotherapy meta-analysis, there was a
trend towards a negative effect of chemotherapy in the small subgroup
of stage IA patients (Arriagada et al., 2010). A 14-gene expression assay
using quantitative PCR was able to discriminate the risk of recurrence in
stage I non-squamous small cell carcinoma with 5-year overall survival
(OS) of 71.4% in low-risk, 58.3% in intermediate-risk and 49.2% in high-
risk patients (Kratz et al., 2012). Genes in this prognostic signature, in-
cluding BRCA1 and YAP1, are central to crucial oncogenic pathways
(Rosell et al., 2011; Kratz et al., 2012). Acquired resistance to KRAS sup-
pression in a KRAS-driven murine lung cancer model involves increased
YAP1 signaling. KRAS and YAP1 converse on the transcription factor FOS
and activate a transcriptional program involved in regulating the epithe-
lial–mesenchymal transition (EMT) (Shao et al., 2012). Therefore, among
the different gene signature models, there are still many inconsistencies.
Although histology was not found to be relevant in the meta-analysis in
early resected NSCLC (Arriagada et al., 2010), recent data indicate that
using the new International Association for the Study of Lung Cancer
(IASLC)/American Thoracic Society (ATS)/European Respiratory Society
(ERS) classiﬁcation, micropapillary- and solid-predominant adenocarci-
nomas have signiﬁcantly worse OS, probability of freedom from recur-
rence and disease-speciﬁc survival than those with lipedic-, acinar- and
papillary-predominant subtypes (Hung et al., 2014). In Chen and Chen's
LCPI, histology was not relevant. They show OS probability at 10 years
in the high-risk group to be 9.5%, while for the intermediate-risk group
this was 39%, and 76% for the low-risk group. However, it could be
convenient to provide data on disease-speciﬁc survival when calculating
survival, since most patients are relatively elderly at time of diagnosis
and can die from non-cancer-related causes.
There is a need for a cancer systems-biology approach that can help to
build the optimal prognostic and predictive gene signatures. Chen and
Chen have tried to resolve this challenge with the aid of ever increasingthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
104 R. Rosell / EBioMedicine 1 (2014) 103–104computing power. Although information regarding intergene regulatory
relationships and their cascades is accumulating, the whole picture re-
garding gene regulatory circuitry remains elusive. Further research is to
be encouraged, employing systems biology-based approaches to identify
the altered regulatory circuitry involved in early NSCLC and decipher the
web of interconnected genes that confer hallmark cancer capabilities
(Hanahan and Weinberg, 2000). The only caveat, as Chen and Chen
have already shown, is that adjuvant chemotherapy can be detrimental.
Also, adjuvant therapy with EGFR tyrosine kinase inhibitors has been
demonstrated to increase the risk of death with a hazard ratio of 3.1 in
the subgroup of adjuvant patients with EGFR mutations (Goss et al.,
2013). This can occur since EGFR inhibition can paradoxically activate
other signaling pathways and therefore decrease survival in patients in
whom surgical resection was performed with curative intent.References
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